
    
      The study consists of 3 periods: screening (2 weeks), treatment period (12 weeks) and
      follow-up (2 weeks). All eligible patients are randomized into one of two treatment groups in
      a ratio of 1:1. During the study patients will continue to receive stable doses of inhaled
      corticosteroids (ICS) with or without the long-acting β2-agonists; when required, patients
      will receive short-acting β2-agonists.The randomized patients will be stratified by the site,
      baseline forced expiratory volume (FEV1) in the range of 55 to 70% and 71% to 85%, and
      therapy of BA (inhaled corticosteroids (ICS) with or without long-acting β2 agonists).

      The Study drug is produced by Hennig Arzneimittel GmbH und Co., Germany.
    
  